The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
Level | Code | Title | |
---|---|---|---|
1 | M | Musculo-skeletal system | |
2 | M01 | Antiinflammatory and antirheumatic products | |
3 | M01A | Antiinflammatory and antirheumatic products, non-steroids | |
4 | M01AB | Acetic acid derivatives and related substances |
Code | Title | |
---|---|---|
M01AB01 | Indometacin | |
M01AB02 | Sulindac | |
M01AB03 | Tolmetin | |
M01AB04 | Zomepirac | |
M01AB05 | Diclofenac | |
M01AB06 | Alclofenac | |
M01AB07 | Bumadizone | |
M01AB08 | Etodolac | |
M01AB09 | Lonazolac | |
M01AB10 | Fentiazac | |
M01AB11 | Acemetacin | |
M01AB12 | Difenpiramide | |
M01AB13 | Oxametacin | |
M01AB14 | Proglumetacin | |
M01AB15 | Ketorolac | |
M01AB16 | Aceclofenac | |
M01AB17 | Bufexamac | |
M01AB51 | Indometacin, combinations | |
M01AB55 | Diclofenac, combinations |
Active Ingredient | Description | |
---|---|---|
Aceclofenac |
Aceclofenac is a non-steroidal agent with marked anti-inflammatory and analgesic properties. The mode of action of aceclofenac is largely based on the inhibition to prostaglandin synthesis. Aceclofenac is a potent inhibitor of the enzyme cyclo-oxygenase, which is involved in the production of prostaglandins. |
|
Acemetacin |
Acemetacin is a glycolic acid ester of indomethacin and the pharmacological activity resulting from acemetacin administration in man is derived from the presence of both acemetacin and indomethacin. The precise pharmacological mode of action of acemetacin is not known. However, unlike other NSAIDs, acemetacin is only a relatively weak inhibitor of prostaglandin synthetase. |
|
Bumadizone |
|
|
Diclofenac |
Diclofenac is a non-steroidal anti-inflammatory drug. The mechanism of action of diclofenac in AK may be related to the inhibition of the cycloxygenase pathway leading to reduced prostaglandin E2 (PGE2) synthesis. In addition, immunohistochemistry (IHC) from skin biopsies ac revealed that the clinical effects of diclofenac in AK are primarily due to anti-inflammatory, anti-angiogenic and possibly anti-proliferative effects and apoptosis-inducing mechanisms. |
|
Indometacin |
Indometacin has anti-inflammatory, antipyretic, and analgesic effects, it is an inhibitor of prostaglandin synthetase. |
|
Ketorolac |
Ketorolac is a non-steroidal anti-inflammatory agent demonstrating analgesic and anti-inflammatory activity. Ketorolac inhibits the cyclo-oxygenase enzyme essential for biosynthesis of prostaglandins. Ketorolac has been shown to reduce prostaglandin levels in the aqueous humour after topical ophthalmic administration. |
|
Proglumetacin |
|
|
Sulindac |
Sulindac is a fluorinated indene with a structural resemblance to indometacin. It has analgesic, anti-inflammatory and antipyretic actions. |
Title | Information Source | Document Type | |
---|---|---|---|
AKIS Solution for injection | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
ALMIRAL Gastro-resistant tablet | Υπουργείο Υγείας (CY) | MPI, EU: SmPC | |
ALMIRAL Gel | Υπουργείο Υγείας (CY) | MPI, EU: SmPC | |
ALMIRAL Solution for injection / infusion | Υπουργείο Υγείας (CY) | MPI, EU: SmPC | |
ALMIRAL Suppositories | Υπουργείο Υγείας (CY) | MPI, EU: SmPC | |
ARESTON Film-coated tablet | Υπουργείο Υγείας (CY) | MPI, EU: SmPC | |
ARTHREXIN Capsule | Health Products Regulatory Authority (ZA) | MPI, Generic | |
CAMBIA Powder for oral solution | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
CATAFAST Powder for oral solution | Medicines Authority (MT) | MPI, EU: SmPC | |
CATAFLAM Sugar coated tablet | Υπουργείο Υγείας (CY) | MPI, EU: SmPC | |
DICLAC Enteric-coated tablet | Υπουργείο Υγείας (CY) | MPI, EU: SmPC | |
DICLAC Solution for injection | Υπουργείο Υγείας (CY) | MPI, EU: SmPC | |
DICLOFLEX Prolonged-release tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
DIFENE Modified‑release capsule | Υπουργείο Υγείας (CY) | MPI, EU: SmPC | |
INDOCID Capsules | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
INDOCID Suppositories | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
INDOREM Hard capsule | Υπουργείο Υγείας (CY) | MPI, EU: SmPC | |
INDYLON Hard gelatine capsule | Υπουργείο Υγείας (CY) | MPI, EU: SmPC | |
LODINE SR Tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
MOTIFENE Capsule, hard | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
MOTIFINE Capsule, hard | Health Products Regulatory Authority (ZA) | MPI, Generic | |
RANTUDIL FORTE Hard capsule | Medicines Authority (MT) | MPI, EU: SmPC | |
REMETHAN Gastro-resistant tablet | Υπουργείο Υγείας (CY) | MPI, EU: SmPC | |
REMETHAN Gel | Υπουργείο Υγείας (CY) | MPI, EU: SmPC | |
REMETHAN Prolonged-release tablet | Υπουργείο Υγείας (CY) | MPI, EU: SmPC | |
REMETHAN Suppository | Υπουργείο Υγείας (CY) | MPI, EU: SmPC | |
TAKS Gastro-resistant tablet | Υπουργείο Υγείας (CY) | MPI, EU: SmPC | |
TAKS Solution for injection or infusion | Υπουργείο Υγείας (CY) | MPI, EU: SmPC | |
VELTEX Capsule / Solution for injection | Health Products Regulatory Authority (ZA) | MPI, Generic | |
VOLTAROL Medicated Plaster | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
VOLTAROL OPTHA MULTIDOSE Eye drops solution | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
VOLTAROL PAIN-EZE EMULGEL Gel for topical administration | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
VOLTAROL RAPID Coated tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
VOLTAROL Suppositories | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
VOLTFAST Powder for oral solution | Health Products Regulatory Authority (IE) | MPI, EU: SmPC | |
ZORVOLEX Capsule | FDA, National Drug Code (US) | MPI, US: SPL/PLR |